SBFM (Sunshine Biopharma) Buyback Yield %: 0.00 (As of Jul. 07, 2026)


SBFM Sunshine Biopharma Inc SBFM
34 GF Score
Price $2.16
GF Value $7.18
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Sunshine Biopharma Buyback Yield %?

Sunshine Biopharma SBFM +3.32% 34 Buyback Yield % is 0.00 as of Jul. 07, 2026. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.18 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 291 Drug Manufacturers companies, Sunshine Biopharma ranks worse than 343642.27% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Sunshine Biopharma's current buyback yield was 0.00%.


Sunshine Biopharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Sunshine Biopharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma Buyback Yield % Chart

Sunshine Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -236.47 -65.34 -69.53 -30.28

Sunshine Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -30.28 0.00

SBFM vs PRFX, CTTH, CVSI: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Buyback Yield % falls into.


SBFM
34GF Score
Sunshine Biopharma Inc SBFM
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunshine Biopharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Sunshine Biopharma's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 1.829) / 6.0393
=-30.28%

Sunshine Biopharma's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 5.1064
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Sunshine Biopharma (SBFM) has a Buyback Yield % of 0.00 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sunshine Biopharma and its competitors. According to the industry distribution chart, Sunshine Biopharma ranks #999999 out of 291 companies in the Drug Manufacturers industry.
Is Sunshine Biopharma's Buyback Yield % too high?
Sunshine Biopharma's current Buyback Yield % is 0.00. Based on the distribution chart, Sunshine Biopharma ranks #999999 out of 291 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's Buyback Yield % compare to PRFX and CTTH?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #999999 out of 291 companies for Buyback Yield %. This places Sunshine Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Sunshine Biopharma and its competitors. Sunshine Biopharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.18, compared to a current price of $2.16 — trading 69.9% below its estimated fair value. The current Buyback Yield % is 0.00. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current Buyback Yield % is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Biopharma (SBFM) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued. The current stock price of $2.16 is trading 69.9% below its estimated GF Value™ of $7.18. GuruFocus considers Sunshine Biopharma to be Possible Value Trap.

Key valuation signals for SBFM:

  • Buyback Yield %: 0.00
  • GF Value™: $7.18 vs. price of $2.16 (69.9% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sunshine Biopharma Business Description

Address 333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score

Get the complete analysis for SBFM

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price
$7.18
GF Value